Clinical Trials Logo

Clinical Trial Summary

This study will evaluate a new critical pathway (use of guideline-based patient identification criteria and for those who meet these criteria, use of dalbavancin) for the treatment of ABSSSI compared to usual care.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02961764
Study type Interventional
Source Allergan
Contact
Status Completed
Phase Phase 4
Start date November 29, 2016
Completion date March 29, 2019

See also
  Status Clinical Trial Phase
Terminated NCT01734694 - Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients Phase 4
Completed NCT02570490 - Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections Phase 3
Completed NCT00949130 - Comparative Study of NXL103 Versus Linezolid in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Phase 2
Completed NCT03176134 - A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018) Phase 3
Completed NCT03137173 - Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections Phase 3
Completed NCT03405064 - Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI) Phase 3